Connect with us

Hi, what are you looking for?

Thursday, Oct 6, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Mindset Pharma discovers 3 novel next-gen psychedelic compounds

Discovery of new drugs follows company decision to extend research outside of tryptamine class, i.e. psilocybin and DMT

Mindset Pharma discovers 3 novel next-gen psychedelic compounds
Photo via Unsplash - Hans Reniers

A Canadian company has now made some discoveries with intriguing implications for the clinical psychedelic industry.

On Wednesday, Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced the discovery of three novel families of non-tryptamine psychedelic compounds.

The company says that its research into new chemical structures outside the realm of classic psychedelic drugs was undertaken with intentions of developing superior neuropsychiatric medications.

Photo via Mindset Pharma

Read more: Mindset Pharma develops patent-pending new technology

Read more: Beond publishes ‘Ibogaine: A Clinical Summary’

Mindset Pharma is a Toronto-based research and development company dedicated to psychedelic drug discovery and development for the treatment of psychiatric and neurological disorders.

Through the use of a so-called fragment-based drug discovery (FBDD) method in unison with a specific medicinal chemistry strategy, the scientists at Mindset have designed and developed three novel, chemically unique, small molecule “non-tryptamine scaffolds” designated as Families 6, 7 and 8.

Additionally, the company has filed provisional patent applications for those three drug families that have yielded favourable freedom-to-operate (FTO) searches with no infringements. Mindset says that some of these new compounds could potentially exhibit improved central nervous system (CNS) penetration and efficacy when administered orally.

“Mindset’s leading drug discovery engine continues to yield innovations with the potential to help patients across the world with neuropsychiatric and neurological disorders. The discovery of new Families 6, 7 and 8 demonstrates our commitment to expanding our Research & Development and strengthening our Intellectual Property (IP) portfolio beyond the classical tryptamines in the psychedelic field,” said James Lanthier, CEO of Mindset Pharma.

“The discovery of these new families further expands our rich pipeline and provides a unique serotonergic receptor profile supporting our goal to design new and elegant drug candidates with increased receptor selectivity and potency profiles. Pre-clinical screening of the new families has shown promising results thus far and we are eagerly looking forward to advancing Mindset’s continued innovations into these new, chemically distinct drug families.”


Follow Mugglehead on Twitter

Like Mugglehead on Facebook





Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like


The company plans to use mushroom tea to treat patients pending regulatory approvals


Company intends to provide ketamine therapy at a much lower price than a visit to the clinic would cost


Company will collaborate with Premier Consulting as regulatory partner and utilize Zylö Therapeutics Z-Pod technology


These relatively new stores remind people about the final days of the cannabis prohibition era in Canada